Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.53 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.53 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.53 |
| ▸ | GRM8 | O00222 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8964242 | 1.00 | MAPT (0.61) | MAPTALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL9064991 | 0.85 | PDE7A (0.50) | MAPTALDH1A1KMOPTPRA | |
| SCHEMBL858833 | 0.84 | APEX1 (0.53) | MAPTALDH1A1APEX1 | |
| SCHEMBL10666135 | 0.82 | ALDH1A1 (0.57) | MAPTALDH1A1GAACYP1A2 | |
| SCHEMBL2003176 | 0.82 | KDM4E (0.52) | MAPTALDH1A1GRM8GRM4GAA | |
| SCHEMBL8904293 | 0.82 | KDM4E (0.52) | MAPTALDH1A1GRM8GRM4GAA | |
| SCHEMBL8610040 | 0.82 | KDM4E (0.52) | MAPTALDH1A1GRM8GRM4GAA | |
| SCHEMBL20547718 | 0.79 | ALDH1A1 (0.55) | MAPTALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL1662813 | 0.79 | ALDH1A1 (0.55) | MAPTALDH1A1TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL6053554 | 0.79 | GRIK1 (0.48) | MAPTALDH1A1GRM8GRM4KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5516936-A | TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-05-14 | — | — | US | claimed |
| EP-0581907-A4 | — | — | 1994-04-06 | — | — | EP | claimed |
| EP-0581907-A1 | INHIBITORS OF KYNURENINASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1994-02-09 | — | — | EP | claimed |
| WO-1992018003-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-10-29 | — | — | WO | claimed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | THE WISTAR INST (US) | 2024-07-04 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | THE WISTAR INSTITUTE (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | NATIONAL INSTITUTES OF HEALTH | 2021-01-14 | — | — | US | disclosed |
| US-5578470-A | USING CYSTEINE | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST (NL) | 1996-11-26 | — | — | US | disclosed |
| US-5516936-A | TREATMENT OF NEUROLOGICAL DISORDERS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-05-14 | — | — | US | disclosed |
| EP-0581907-A4 | — | — | 1994-04-06 | — | — | EP | disclosed |
| EP-0581907-A1 | INHIBITORS OF KYNURENINASE | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1994-02-09 | — | — | EP | disclosed |
| WO-1992018003-A1 | INHIBITORS OF KYNURENINASE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008043-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | MAPT 4823/4885ALDH1A1 2686/4885TXNRD1 307/4885 |
| US-11833137-B2 | Substituted chromenones, IRE1 inhibitors, and methods of using same | XBP1, ERN1, ERN2 | MAPT 4823/4885ALDH1A1 2686/4885TXNRD1 307/4885 |
| US-20240216346-A1 | Substituted Chromenones, IRE1 Inhibitors, and Methods of Using Same | XBP1, ERN1, ERN2 | MAPT 4804/4885ALDH1A1 2667/4885TXNRD1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.